Eli Lilly and Company (NYSE:LLY) Shares Sold by KRS Capital Management LLC

KRS Capital Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 4.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,754 shares of the company’s stock after selling 235 shares during the quarter. Eli Lilly and Company accounts for approximately 3.0% of KRS Capital Management LLC’s investment portfolio, making the stock its 4th largest position. KRS Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,699,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Tidemark LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares in the last quarter. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Finally, St. Johns Investment Management Company LLC boosted its holdings in shares of Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after buying an additional 37 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 17,229 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the transaction, the insider now owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 17,229 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $902.38, for a total value of $15,547,105.02. Following the completion of the transaction, the insider now owns 97,556,910 shares of the company’s stock, valued at approximately $88,033,404,445.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 789,704 shares of company stock worth $672,385,964. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Down 0.4 %

Shares of Eli Lilly and Company stock opened at $905.38 on Friday. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $915.54. The firm has a market cap of $860.48 billion, a PE ratio of 133.34, a P/E/G ratio of 1.97 and a beta of 0.36. The stock has a fifty day moving average price of $814.40 and a 200-day moving average price of $739.86. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period last year, the firm posted $1.62 EPS. The business’s revenue was up 26.0% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Bank of America restated a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Truist Financial reiterated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.